Kirin Brewery Company

Kirin Holdings is a global conglomerate that has successfully transitioned from its traditional brewing roots into a major force in the life sciences and healthcare industries. The company's pharmaceutical business, primarily conducted through its subsidiary Kyowa Kirin, focuses on core therapeutic areas such as oncology, nephrology, central nervous system, and immunology. Kirin is a pioneer in antibody technology, utilizing its proprietary POTELLIGENT platform to develop high-potency biologics like Crysvita and Poteligeo. Additionally, the group's Health Science division leverages advanced fermentation and biotechnology to create functional food ingredients, including its proprietary Lactococcus lactis strain Plasma for immune support. With the strategic acquisition of Orchard Therapeutics, Kirin has expanded its portfolio into cutting-edge hematopoietic stem cell gene therapies for rare diseases.